拉泽替尼治疗携带罕见EGFR突变非小细胞肺癌患者的II期多中心试验
这项单臂多中心II期试验纳入36例携带罕见EGFR突变(排除20号外显子插入)的晚期NSCLC患者,接受拉泽替尼240 mg每日一次治疗。客观缓解率为50.0%(95%CI 34.5%-65.5%),达到主要终点;中位无进展生存期10.8个月,中位缓解持续时间15.1个月;3级及以上治疗中出现的不良事件发生率为33.3%。
要点
- 拉泽替尼240 mg每日一次治疗罕见EGFR突变晚期NSCLC,客观缓解率50.0%(95%CI 34.5%-65.5%)。
- 主要罕见突变(G719X、L861Q、S768I)患者客观缓解率为54.8%(17/31)。
- G719X突变客观缓解率61%、中位无进展生存期20.3个月;S768I客观缓解率60%;L861Q客观缓解率58%、中位无进展生存期9.5个月。
核心结论
- 拉泽替尼在携带罕见EGFR突变的NSCLC患者中显示出有前景的疗效和可控的安全性,尤其是G719X、S768I和L861Q亚型。
- 这些结果提示拉泽替尼可能成为这一治疗选择有限且异质性患者群体的有效治疗选择。
研究设计与样本
- 单臂、多中心II期试验,纳入携带罕见EGFR突变(排除20号外显子插入)的晚期NSCLC患者。
- 患者接受拉泽替尼240 mg每日一次治疗,直至疾病进展或出现不可接受的毒性。
- 共纳入36例患者;主要终点为按实体瘤疗效评价标准1.1版评估的客观缓解率。
主要发现
- 36例患者中客观缓解率为50.0%(95%CI 34.5%-65.5%),包括18例部分缓解,达到主要终点。
- 疾病控制率为88.9%(95%CI 74.1%-96.2%)。
- 主要罕见突变(G719X、L861Q、S768I)患者客观缓解率为54.8%(17/31)。
- 中位无进展生存期为10.8个月(95%CI 4.4-19.2),中位缓解持续时间为15.1个月。
- G719X突变客观缓解率61%、中位无进展生存期20.3个月;S768I客观缓解率60%;L861Q客观缓解率58%、中位无进展生存期9.5个月。
关键数值与推荐
- 客观缓解率50.0%(95%CI 34.5%-65.5%),18例部分缓解。
- 疾病控制率88.9%(95%CI 74.1%-96.2%)。
- 主要罕见突变(G719X、L861Q、S768I)客观缓解率54.8%(17/31)。
- 中位无进展生存期10.8个月(95%CI 4.4-19.2),中位缓解持续时间15.1个月。
临床怎么用
- 所有患者均发生治疗中出现的不良事件,3级及以上事件发生率为33.3%。
- 最常见的不良事件为皮疹(47.2%)、瘙痒(36.1%)和肌肉痉挛(33.3%)。
- 作者认为拉泽替尼可能成为携带罕见EGFR突变(尤其是G719X、S768I和L861Q亚型)NSCLC患者的有效治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Uncommon EGFR mutations comprise 10% to 20% of all EGFR mutations in NSCLC and generally report reduced responsiveness to EGFR tyrosine kinase inhibitors (TKIs). Lazertinib, a third-generation EGFR-TKI, has found efficacy in common EGFR mutations, but its potential in uncommon mutations remains unexplored. This study investigated the efficacy and safety of lazertinib in patients with NSCLC with uncommon EGFR mutations. METHOD: This single-arm, multicenter phase II trial enrolled patients with advanced NSCLC harboring uncommon EGFR mutations excluding exon 20 insertions. Patients received lazertinib 240 mg daily until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety. RESULTS: Among 36 patients enrolled, the ORR was 50.0% (95% confidence interval [CI]: 34.5%-65.5%), with 18 partial responses, meeting the primary end point. Disease control rate was 88.9% (95% CI: 74.1%-96.2%). Patients with major uncommon mutations (G719X, L861Q, S768I) reported an ORR of 54.8% (17/31). Median PFS was 10.8 months (95% CI: 4.4-19.2), and median DoR was 15.1 months. G719X mutations reported the highest response (ORR 61%, median PFS 20.3 months), followed by S768I (ORR 60%) and L861Q (ORR 58%, median PFS 9.5 months). Treatment-emergent adverse events occurred in all patients, with grade 3 or higher events in 33.3%; most common were rash (47.2%), pruritus (36.1%), and muscle spasms (33.3%). CONCLUSIONS: Lazertinib reported promising efficacy and a manageable safety profile in patients with NSCLC with uncommon EGFR mutations, particularly for G719X, S768I, and L861Q subtypes. These results suggest lazertinib could be an effective treatment option for this heterogeneous patient population with limited therapeutic alternatives.
引用
- Park S, Ahn HK, Lee S, et al. Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial. J Thorac Oncol. 2025. PMID: 40350080. doi:10.1016/j.jtho.2025.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。